The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

Pharmacological Research

Volumn 58, Issue 1, 2008, Pages 1-7

  Qvist, Per ^a   Bay Jensen, Anne Christine ^a   Christiansen, Claus ^a   Dam, Erik B ^a   Pastoureau, Philippe ^b   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

DMOAD; Osteoarthritis; Treatment

Indexed keywords

ADALIMUMAB; AMG 108; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; AZD 8955; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CP 544439; CYTOKINE RECEPTOR ANTAGONIST; DIACETYLRHEIN; DISEASE MODIFYING OSTEOARTHRITIS DRUG; DOXYCYCLINE; ENZYME INHIBITOR; GLUCOSAMINE; HYALURONIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PG 116800; PLACEBO; PROTEOGLYCAN; REBIMASTAT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; SALCATONIN; SD 6010; STEROID; TANOMASTAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 170523;

ARTHRALGIA; CHONDROPROTECTION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; IMAGE ANALYSIS; JOINT DESTRUCTION; JOINT RADIOGRAPHY; JOINT STIFFNESS; MUSCULOSKELETAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTHRAQUINONES; ANTIRHEUMATIC AGENTS; CALCITONIN; CYTOKINES; DIPHOSPHONATES; DOXYCYCLINE; GLUCOSAMINE; HUMANS; MATRIX METALLOPROTEINASES; NITRIC OXIDE SYNTHASE TYPE II; OSTEOARTHRITIS;

EID: 50649122963     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.06.001     Document Type: Review

References (63)

1. Woolf A.D., and Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 81 (2003) 646-656
2. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-799
3. Goldring M.B., and Goldring S.R. Osteoarthritis. J Cell Physiol 213 (2007) 626-634
4. Pritzker K.P., Gay S., Jimenez S.A., et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 14 (2006) 13-29
5. Kellgren J.H., and Lawrence J.S. Osteo-arthrosis and disk degeneration in an urban population. Ann Rheum Dis 17 (1958) 388-397
6. Lajeunesse D., Hilal G., Pelletier J.P., and Martel-Pelletier J. Subchondral bone morphological and biochemical alterations in osteoarthritis. Osteoarthritis Cartilage 7 (1999) 321-322
7. Karsdal M.A., Leeming D.J., Dam E.B., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 16 (2008) 638-646
8. Krasnokutsky S., Samuels J., and Abramson S.B. Osteoarthritis in 2007. Bull NYU Hosp Jt Dis 65 (2007) 222-228
9. Bingham III C.O., Buckland-Wright J.C., Garnero P., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54 (2006) 3494-3507
10. Krzeski P., Buckland-Wright C., Bálint G., et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomised, 12-month, double-blind, placebo-controlled study. Arthritis Rheum 9 (2007) R109
11. Reijman M., Hazes J.M., Bierma-Zeinstra S.M., et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50 (2004) 2471-2478
12. Pessis E., Drape J.L., Ravaud P., Chevrot A., and Ayral M.D.X. Assessment of progression in knee osteoarthritis: results of a 1 year study comparing arthroscopy and MRI. Osteoarthritis Cartilage 11 (2003) 361-369
13. Wluka A.E., Wolfe R., Stuckey S., and Cicuttini F.M. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis?. Ann Rheum Dis 63 (2004) 264-268
14. Cicuttini F.M., Jones G., Forbes A., and Wluka A.E. Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 63 (2004) 1124-1127
15. van der Kraan P.M., and van den Berg W.B. Osteophytes: relevance and biology. Osteoarthritis Cartilage 15 (2007) 237-244
16. Blumenkrantz G., Lindsey C.T., Dunn T.C., et al. A pilot, two-year longitudinal study of the interrelationship between trabecular bone and articular cartilage in the osteoarthritic knee. Osteoarthritis Cartilage 12 (2004) 997-1005
17. Rousseau J.C., and Delmas P.D. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3 (2007) 346-356
18. Garnero P.G. New biochemical markers of cartilage turnover in osteoarthritis: recent developments and remaining challenges. BoneKey-Osteovision 4 (2007) 7-18
19. Birmingham J.D., Vilim V., and Kraus V.B. Collagen biomarkers in arthritis applications. Biomarker Insights 2 (2006) 61-76
20. Schaller S., Henriksen K., Hoegh-Andersen P., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol 3 (2005) 553-580
21. Li Y., Xu L., and Olsen B.R. Lessons from genetic forms of osteoarthritis for the pathogenesis of the disease. Osteoarthritis Cartilage 15 (2007) 1101-1105
22. Dedrick D.K., Goldstein S.A., Brandt K.D., O'Connor B.L., Goulet R.W., and Albrecht M. A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum 36 (1993) 1460-1467
23. Messent E.A., Ward R.J., Tonkin C.J., and Buckland-Wright C. Tibial cancellous bone changes in patients with knee osteoarthritis. A short-term longitudinal study using Fractal Signature Analysis. Osteoarthritis Cartilage 13 (2005) 463-470
24. Dam E., Christiansen C., and Karsdal M.A. Elevated urinary CTX-II levels predict OA progression and cartilage loss over 21 months. Osteoarthritis Cartilage 15 (2007) C64-C65
25. Brandt K.D., and Mazzuca S.A. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum 52 (2005) 3349-3359
26. Abramson S.B., and Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev 58 (2006) 212-225
27. Pelletier J.P., Martel-Pelletier J., and Raynauld J.P. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Res Ther 8 (2006) 206
28. Pelletier J.P., and Martel-Pelletier J. DMOAD developments: present and future. Bull NYU Hosp Jt Dis 65 (2007) 242-248
29. Hudson M.P., Armstrong P.W., Ruzyllo W., et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (prevention of myocardial infarction early remodeling) trial. J Am Coll Cardiol 48 (2006) 15-20
30. Leff R.L., Elias I., Ionescu M., Reiner A., and Poole A.R. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 30 (2003) 544-549
31. Bissett D., O'Byrne K.J., von Pawel J., et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23 (2005) 842-849
32. Miller K.D., Saphner T.J., Waterhouse D.M., et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10 (2004) 1971-1975
33. King J., Zhao J., Clingan P., and Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23 (2003) 639-645
34. Hurskainen T.L., Hirohata S., Seldin M.F., and Apte S.S. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J Biol Chem 274 (1999) 25555-25563
35. Stanton H., Rogerson F.M., East C.J., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434 (2005) 648-652
36. Glasson S.S., Askew R., Sheppard B., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434 (2005) 644-648
37. Spector T.D., Conaghan P.G., Buckland-Wright J.C., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 7 (2005) R625-R633
38. Garnero P., Aronstein W.S., Cohen S.B., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the knee osteoarthritis structural arthritis randomized clinical trial. Osteoarthritis Cartilage (2007) [Epub ahead of print]
39. Buckland-Wright J.C., Messent E.A., Bingham III C.O., Ward R.J., and Tonkin C. A 2 year longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology 46 (2007) 257-264
40. Pelletier J.P., Lajeunesse D., Reboul P., et al. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol 28 (2001) 814-824
41. Palmer R.M., Hickery M.S., Charles I.G., Moncada S., and Bayliss M.T. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 193 (1993) 398-405
42. Kobayashi M., Squires G.R., Mousa A., et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 52 (2005) 128-135
43. Martel-Pelletier J., McCollum R., DiBattista J., et al. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 35 (1992) 530-540
44. ®) in patients with osteoarthritis of the knee. Arthritis Rheum 52 (2005) S507
45. Duff G.W. Arthritis and interleukins. Br J Rheumatol 27 (1988) 2-5
46. Kirkham B. Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis 50 (1991) 395-400
47. van der Bijl A.E., Breedveld F.C., Antoni C.E., et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol (2008) [Epub ahead of print]
48. Magnano M.D., Chakravarty E.F., Broudy C., et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 34 (2007) 1323-1327
49. Karsdal M.A., Tanko L.B., Riis B.J., et al. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?. Osteoarthritis Cartilage 14 (2006) 617-624
50. Manicourt D.H., Azria M., Mindeholm L., Thonar E.J., and Devogelaer J.P. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54 (2006) 3205-3211
51. Bagger Y.Z., Tanko L.B., Alexandersen P., et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 12 (2005) 12-17
52. Behets C., Williams J.M., Chappard D., Devogelaer J.P., and Manicourt D.H. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 19 (2004) 1821-1826
53. Sondergaard B.C., Oestergaard S., Christiansen C., Tankó L.B., and Karsdal M.A. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 56 (2007) 2674-2678
54. Vuolteenaho K., Moilanen T., Knowles R.G., and Moilanen E. The role of nitric oxide in osteoarthritis. Scand J Rheumatol 36 (2007) 247-258
55. Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen,NO-naproxen. Drugs R D 2007;8:255-8.
56. Hanemaaijer R., Van Lent N., Sorsa T., Salo T., Konttinen Y.T., and Lindeman J. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines. In: Nelson M., Hillen W., and Greenwald R.A. (Eds). Tetracyclines in biology, chemistry and medicine (2001), Birkhauser Verlag, Basel 267-281
57. Brandt K.D., Mazzuca S.A., Katz B.P., et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 52 7 (2005) 2015-2025
58. Reginster J.Y., Deroisy R., Rovati L.C., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
59. Clegg D.O., Reda D.J., Harris C.L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354 (2006) 795-808
60. Vlad S.C., LaValley M.P., McAlindon T.E., and Felson D.T. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum 56 (2007) 2267-2277
61. Frech T.M., and Clegg D.O. The utility of nutraceuticals in the treatment of osteoarthritis. Curr Rheumatol Rep 9 (2007) 25-30
62. Dougados M., Nguyen M., Berdah L., Maziéres B., Vignon E., and Lequesne M. ECHODIAH Investigators Study Group. evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 44 (2001) 2539-2547
63. Pham T., Le Henanff A., Ravaud P., Dieppe P., Paolozzi L., and Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomized controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 63 (2004) 1611-1617